Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EBITDA (2021 - 2025)

Historic EBITDA for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $1.6 million.

  • Verrica Pharmaceuticals' EBITDA rose 10785.84% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.4 million, marking a year-over-year increase of 7926.9%. This contributed to the annual value of -$65.9 million for FY2024, which is 160.61% up from last year.
  • As of Q3 2025, Verrica Pharmaceuticals' EBITDA stood at $1.6 million, which was up 10785.84% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' EBITDA ranged from a high of $1.6 million in Q3 2025 and a low of -$24.8 million during Q3 2023
  • For the 5-year period, Verrica Pharmaceuticals' EBITDA averaged around -$10.4 million, with its median value being -$10.2 million (2022).
  • As far as peak fluctuations go, Verrica Pharmaceuticals' EBITDA crashed by 2111864.41% in 2023, and later surged by 10993.03% in 2025.
  • Over the past 5 years, Verrica Pharmaceuticals' EBITDA (Quarter) stood at -$9.6 million in 2021, then soared by 38.3% to -$5.9 million in 2022, then tumbled by 316.97% to -$24.6 million in 2023, then skyrocketed by 53.64% to -$11.4 million in 2024, then skyrocketed by 114.26% to $1.6 million in 2025.
  • Its EBITDA stands at $1.6 million for Q3 2025, versus $1.5 million for Q2 2025 and -$8.1 million for Q1 2025.